SWOG S1400B(NCT02785913):GDC-0032(taselisib)治疗既往经治PI3K阳性IV期鳞状细胞肺癌的II期研究(Lung-MAP子研究)
S1400B是一项生物标志物驱动的Lung-MAP子研究,评估PI3K抑制剂taselisib在PI3K通路激活的鳞状非小细胞肺癌(sqNSCLC)患者中的疗效。26例可评估患者接受taselisib 4 mg口服每日一次,主要分析人群(PAP)21例。 interim分析时因无效提前终止,PAP中仅1例缓解(缓解率5%,95%CI 0%-24%),中位无进展生存期2.9个月,中位总生存期5.9个月,观察到2例可能治疗相关死亡。
要点
- taselisib在PIK3CA突变sqNSCLC中因无效提前终止,PAP缓解率仅5%。
- PAP中位PFS为2.9个月(95%CI 1.8-4.0),中位OS为5.9个月(95%CI 4.2-7.8)。
- 观察到2例可能治疗相关死亡(呼吸衰竭、心脏骤停各1例)。
核心结论
- S1400B评估taselisib在PIK3CA突变sqNSCLC中未达到主要终点, interim无效分析后终止。
- 该试验独特地记录了sqNSCLC中PIK3CA突变的多样性。
研究设计与样本
- S1400B是生物标志物驱动的Lung-MAP子研究,评估PI3K抑制剂taselisib(GDC-0032)在PI3K通路激活的sqNSCLC患者中的疗效。
- eligible患者需经下一代测序检出肿瘤PIK3CA改变,且至少一线含铂治疗后疾病进展。
- 患者接受taselisib 4 mg口服每日一次。
- 主要分析人群(PAP)为携带被认为与PI3K抑制剂临床获益相关的置换突变的患者亚组。
- 主要终点为RECIST 1.1版评估的缓解;次要终点包括无进展生存期、总生存期和缓解持续时间。
主要发现
- 26例接受taselisib治疗的患者构成全可评估人群(FEP);21例构成PAP。
- FEP中位年龄68岁(范围53-83岁),19例为男性(73%)。
- 研究在 interim分析时因无效终止,PAP中1例缓解(缓解率5%,95%CI 0%-24%)。
- 观察到2例可能治疗相关死亡(1例呼吸衰竭,1例心脏骤停);1例患者发生4级不良事件,11例发生3级不良事件。
- PAP组中位无进展生存期和总生存期分别为2.9个月(95%CI 1.8-4.0个月)和5.9个月(95%CI 4.2-7.8个月);FEP中这些数值几乎相同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S1400B is a biomarker-driven Lung-MAP substudy evaluating the phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (sqNSCLC). METHODS: Eligible patients had tumoral phosphatidylinositol-4,5-biphosphate 3 kinase catalytic subunit alpha (PIK3CA) alterations by next-generation sequencing and disease progression after at least one line of platinum-based therapy. Patients received 4-mg taselisib orally daily. The primary analysis population (PAP) was a subset of patients having substitution mutations believed to be associated with clinical benefit of PI3K inhibitors. Primary endpoint was response by Response Evaluation Criteria in Solid Tumors version 1.1; secondary endpoints included progression-free survival, overall survival and duration of response. RESULTS: Twenty-six patients treated with taselisib comprised the full evaluable population (FEP); 21 patients comprised the PAP. Median age for patients in the FEP was 68 years (range: 53-83 years), 19 were male (73%). The study was closed for futility at interim analysis with one responder in the PAP (5% response rate, 95% confidence interval [CI]: 0%-24%). Two possibly treatment-related deaths (one respiratory failure, one cardiac arrest) were observed; one patient had grades 4 and 11 had grade 3 adverse events. Median progression-free survival and overall survival in the PAP group were 2.9 months (95% CI: 1.8-4.0 mo) and 5.9 months (95% CI: 4.2-7.8 mo), respectively. These numbers were nearly the same in the FEP. CONCLUSIONS: Study S1400B evaluating taselisib in PIK3CA-altered sqNSCLC failed to meet its primary endpoint and was closed after an interim futility analysis. The trial is unique in cataloguing the diversity of PIK3CA mutations in sqNSCLC.
引用
- Langer CJ, Redman MW, Wade JL, et al. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019. PMID: 31158500. doi:10.1016/j.jtho.2019.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。